Loading…

Ultrasound-guided percutaneous microwave ablation assisted by three-dimensional visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion for larger hepatic hilum hepatocellular (D ≥ 3 cm): preliminary results

To assess the clinical efficiency of ultrasound-guided percutaneous microwave ablation (US-PMWA) assisted by three-dimensional (3D) visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion (PTCD-ICSP) for larger hep...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2017-10, Vol.8 (45), p.79742-79749
Main Authors: Li, Xin, Yu, Jie, Liang, Ping, Yu, Xiaoling, Cheng, Zhigang, Han, Zhiyu, Duan, Shaobo, Zheng, Jiasheng
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c356t-5ab2cc8453959830dbbd6afe0addc83dee22a5c0a4a0de9c6e1ac3453fd98a23
cites cdi_FETCH-LOGICAL-c356t-5ab2cc8453959830dbbd6afe0addc83dee22a5c0a4a0de9c6e1ac3453fd98a23
container_end_page 79749
container_issue 45
container_start_page 79742
container_title Oncotarget
container_volume 8
creator Li, Xin
Yu, Jie
Liang, Ping
Yu, Xiaoling
Cheng, Zhigang
Han, Zhiyu
Duan, Shaobo
Zheng, Jiasheng
description To assess the clinical efficiency of ultrasound-guided percutaneous microwave ablation (US-PMWA) assisted by three-dimensional (3D) visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion (PTCD-ICSP) for larger hepatic hilum hepatocellular carcinoma (HH-HCC) (D ≥ 3 cm). The combination therapy was performed in 14 patients from Sep 2011 to May 2017. The major outcomes for assessment were biliary duct complications, local tumor recurrence, distant recurrence and overall survival rates. Median follow-up period was 26 months. The series of 3D visualization operative treatment planning, PTCD-ICSP and US-PMWA were successfully performed and complete ablation was achieved in all cases. The mean session for one tumor was 1.0 ± 0.4. The mean ablation time for per tumor was 1805 ± 567s. The saline volume used for the PTCD-ICSP was 250-450 ml per session. The 1-, 2-, and 3-year local tumor recurrence rates were 7.1%, 14.3%, and 35.7%, the 1-, 2-, and 3-year distant recurrence rates were 0%, 14.3%, and 28.6%, and 1-, 2-, and 3-year overall survival rates were 100%, 92.9%, and 71.4%, respectively. No severe complications related to ablation occurred. US-PMWA assisted by 3D visualization operative treatment planning system and PTCD-ICSP appears to be a safe, effective and innovative technique for management for larger HH-HCCs, which improved the prognosis.
doi_str_mv 10.18632/oncotarget.19275
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5668087</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1961638678</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-5ab2cc8453959830dbbd6afe0addc83dee22a5c0a4a0de9c6e1ac3453fd98a23</originalsourceid><addsrcrecordid>eNpdks1u1DAQxwMC0ar0Abgg3yiHlCReZxMOSKiUD6kSl3KOJvYkMXLs4I-tljfgQXgxnqSz3bYUfLGt-c1__mNPlr0oi9OyqXn1xlnpIvgR42nZVmvxODss21WbV0LwJw_OB9lxCN8LWmK1bqr2WXZQtWXRcLE6fPTqm4kegktW5WPSChVb0MsUwaJLgc1aencFG2TQG4jaWQYh6BAJ7LcsTh4xV3pGGygGhm10SGD0zz3rSIxOlB49QiQsssWAtdqOLGxJZmZg_6tJhmyYcKFEyeTkiB81SSsP2sKI7ErHiWlLnEoyUkRO2hhyFKiyxZ3akHZ-2OA8M7s38uxOkNA0729OojGJ4uzkA_vz6zfjTM6v37LFo9Ez1fJb5jEkE8Pz7OkAJuDx7X6UXX48vzz7nF98_fTl7P1FLrmoYy6gr6RsVoK3om14ofpe1TBgAUrJhivEqgIhC1hBobCVNZYgOeGDahuo-FH2bi-7pH5GJXHXpOkWr2cy0znQ3b8Rq6dudJtO1HVTNGsSOLkV8O5HwhC7WYddm_u37cq2Lmve1OuG0HKP0g-H4HG4L1MW3c2IdX9HrLsZMcp5-dDffcbdQPFrhf_ekQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1961638678</pqid></control><display><type>article</type><title>Ultrasound-guided percutaneous microwave ablation assisted by three-dimensional visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion for larger hepatic hilum hepatocellular (D ≥ 3 cm): preliminary results</title><source>PubMed Central</source><creator>Li, Xin ; Yu, Jie ; Liang, Ping ; Yu, Xiaoling ; Cheng, Zhigang ; Han, Zhiyu ; Duan, Shaobo ; Zheng, Jiasheng</creator><creatorcontrib>Li, Xin ; Yu, Jie ; Liang, Ping ; Yu, Xiaoling ; Cheng, Zhigang ; Han, Zhiyu ; Duan, Shaobo ; Zheng, Jiasheng</creatorcontrib><description>To assess the clinical efficiency of ultrasound-guided percutaneous microwave ablation (US-PMWA) assisted by three-dimensional (3D) visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion (PTCD-ICSP) for larger hepatic hilum hepatocellular carcinoma (HH-HCC) (D ≥ 3 cm). The combination therapy was performed in 14 patients from Sep 2011 to May 2017. The major outcomes for assessment were biliary duct complications, local tumor recurrence, distant recurrence and overall survival rates. Median follow-up period was 26 months. The series of 3D visualization operative treatment planning, PTCD-ICSP and US-PMWA were successfully performed and complete ablation was achieved in all cases. The mean session for one tumor was 1.0 ± 0.4. The mean ablation time for per tumor was 1805 ± 567s. The saline volume used for the PTCD-ICSP was 250-450 ml per session. The 1-, 2-, and 3-year local tumor recurrence rates were 7.1%, 14.3%, and 35.7%, the 1-, 2-, and 3-year distant recurrence rates were 0%, 14.3%, and 28.6%, and 1-, 2-, and 3-year overall survival rates were 100%, 92.9%, and 71.4%, respectively. No severe complications related to ablation occurred. US-PMWA assisted by 3D visualization operative treatment planning system and PTCD-ICSP appears to be a safe, effective and innovative technique for management for larger HH-HCCs, which improved the prognosis.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.19275</identifier><identifier>PMID: 29108354</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Clinical Research Paper</subject><ispartof>Oncotarget, 2017-10, Vol.8 (45), p.79742-79749</ispartof><rights>Copyright: © 2017 Li et al. 2017</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-5ab2cc8453959830dbbd6afe0addc83dee22a5c0a4a0de9c6e1ac3453fd98a23</citedby><cites>FETCH-LOGICAL-c356t-5ab2cc8453959830dbbd6afe0addc83dee22a5c0a4a0de9c6e1ac3453fd98a23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668087/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668087/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29108354$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Xin</creatorcontrib><creatorcontrib>Yu, Jie</creatorcontrib><creatorcontrib>Liang, Ping</creatorcontrib><creatorcontrib>Yu, Xiaoling</creatorcontrib><creatorcontrib>Cheng, Zhigang</creatorcontrib><creatorcontrib>Han, Zhiyu</creatorcontrib><creatorcontrib>Duan, Shaobo</creatorcontrib><creatorcontrib>Zheng, Jiasheng</creatorcontrib><title>Ultrasound-guided percutaneous microwave ablation assisted by three-dimensional visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion for larger hepatic hilum hepatocellular (D ≥ 3 cm): preliminary results</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>To assess the clinical efficiency of ultrasound-guided percutaneous microwave ablation (US-PMWA) assisted by three-dimensional (3D) visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion (PTCD-ICSP) for larger hepatic hilum hepatocellular carcinoma (HH-HCC) (D ≥ 3 cm). The combination therapy was performed in 14 patients from Sep 2011 to May 2017. The major outcomes for assessment were biliary duct complications, local tumor recurrence, distant recurrence and overall survival rates. Median follow-up period was 26 months. The series of 3D visualization operative treatment planning, PTCD-ICSP and US-PMWA were successfully performed and complete ablation was achieved in all cases. The mean session for one tumor was 1.0 ± 0.4. The mean ablation time for per tumor was 1805 ± 567s. The saline volume used for the PTCD-ICSP was 250-450 ml per session. The 1-, 2-, and 3-year local tumor recurrence rates were 7.1%, 14.3%, and 35.7%, the 1-, 2-, and 3-year distant recurrence rates were 0%, 14.3%, and 28.6%, and 1-, 2-, and 3-year overall survival rates were 100%, 92.9%, and 71.4%, respectively. No severe complications related to ablation occurred. US-PMWA assisted by 3D visualization operative treatment planning system and PTCD-ICSP appears to be a safe, effective and innovative technique for management for larger HH-HCCs, which improved the prognosis.</description><subject>Clinical Research Paper</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpdks1u1DAQxwMC0ar0Abgg3yiHlCReZxMOSKiUD6kSl3KOJvYkMXLs4I-tljfgQXgxnqSz3bYUfLGt-c1__mNPlr0oi9OyqXn1xlnpIvgR42nZVmvxODss21WbV0LwJw_OB9lxCN8LWmK1bqr2WXZQtWXRcLE6fPTqm4kegktW5WPSChVb0MsUwaJLgc1aencFG2TQG4jaWQYh6BAJ7LcsTh4xV3pGGygGhm10SGD0zz3rSIxOlB49QiQsssWAtdqOLGxJZmZg_6tJhmyYcKFEyeTkiB81SSsP2sKI7ErHiWlLnEoyUkRO2hhyFKiyxZ3akHZ-2OA8M7s38uxOkNA0729OojGJ4uzkA_vz6zfjTM6v37LFo9Ez1fJb5jEkE8Pz7OkAJuDx7X6UXX48vzz7nF98_fTl7P1FLrmoYy6gr6RsVoK3om14ofpe1TBgAUrJhivEqgIhC1hBobCVNZYgOeGDahuo-FH2bi-7pH5GJXHXpOkWr2cy0znQ3b8Rq6dudJtO1HVTNGsSOLkV8O5HwhC7WYddm_u37cq2Lmve1OuG0HKP0g-H4HG4L1MW3c2IdX9HrLsZMcp5-dDffcbdQPFrhf_ekQ</recordid><startdate>20171003</startdate><enddate>20171003</enddate><creator>Li, Xin</creator><creator>Yu, Jie</creator><creator>Liang, Ping</creator><creator>Yu, Xiaoling</creator><creator>Cheng, Zhigang</creator><creator>Han, Zhiyu</creator><creator>Duan, Shaobo</creator><creator>Zheng, Jiasheng</creator><general>Impact Journals LLC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20171003</creationdate><title>Ultrasound-guided percutaneous microwave ablation assisted by three-dimensional visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion for larger hepatic hilum hepatocellular (D ≥ 3 cm): preliminary results</title><author>Li, Xin ; Yu, Jie ; Liang, Ping ; Yu, Xiaoling ; Cheng, Zhigang ; Han, Zhiyu ; Duan, Shaobo ; Zheng, Jiasheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-5ab2cc8453959830dbbd6afe0addc83dee22a5c0a4a0de9c6e1ac3453fd98a23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Clinical Research Paper</topic><toplevel>online_resources</toplevel><creatorcontrib>Li, Xin</creatorcontrib><creatorcontrib>Yu, Jie</creatorcontrib><creatorcontrib>Liang, Ping</creatorcontrib><creatorcontrib>Yu, Xiaoling</creatorcontrib><creatorcontrib>Cheng, Zhigang</creatorcontrib><creatorcontrib>Han, Zhiyu</creatorcontrib><creatorcontrib>Duan, Shaobo</creatorcontrib><creatorcontrib>Zheng, Jiasheng</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Xin</au><au>Yu, Jie</au><au>Liang, Ping</au><au>Yu, Xiaoling</au><au>Cheng, Zhigang</au><au>Han, Zhiyu</au><au>Duan, Shaobo</au><au>Zheng, Jiasheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ultrasound-guided percutaneous microwave ablation assisted by three-dimensional visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion for larger hepatic hilum hepatocellular (D ≥ 3 cm): preliminary results</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2017-10-03</date><risdate>2017</risdate><volume>8</volume><issue>45</issue><spage>79742</spage><epage>79749</epage><pages>79742-79749</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>To assess the clinical efficiency of ultrasound-guided percutaneous microwave ablation (US-PMWA) assisted by three-dimensional (3D) visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion (PTCD-ICSP) for larger hepatic hilum hepatocellular carcinoma (HH-HCC) (D ≥ 3 cm). The combination therapy was performed in 14 patients from Sep 2011 to May 2017. The major outcomes for assessment were biliary duct complications, local tumor recurrence, distant recurrence and overall survival rates. Median follow-up period was 26 months. The series of 3D visualization operative treatment planning, PTCD-ICSP and US-PMWA were successfully performed and complete ablation was achieved in all cases. The mean session for one tumor was 1.0 ± 0.4. The mean ablation time for per tumor was 1805 ± 567s. The saline volume used for the PTCD-ICSP was 250-450 ml per session. The 1-, 2-, and 3-year local tumor recurrence rates were 7.1%, 14.3%, and 35.7%, the 1-, 2-, and 3-year distant recurrence rates were 0%, 14.3%, and 28.6%, and 1-, 2-, and 3-year overall survival rates were 100%, 92.9%, and 71.4%, respectively. No severe complications related to ablation occurred. US-PMWA assisted by 3D visualization operative treatment planning system and PTCD-ICSP appears to be a safe, effective and innovative technique for management for larger HH-HCCs, which improved the prognosis.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>29108354</pmid><doi>10.18632/oncotarget.19275</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1949-2553
ispartof Oncotarget, 2017-10, Vol.8 (45), p.79742-79749
issn 1949-2553
1949-2553
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5668087
source PubMed Central
subjects Clinical Research Paper
title Ultrasound-guided percutaneous microwave ablation assisted by three-dimensional visualization operative treatment planning system and percutaneous transhepatic cholangial drainage with intraductal chilled saline perfusion for larger hepatic hilum hepatocellular (D ≥ 3 cm): preliminary results
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T17%3A40%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ultrasound-guided%20percutaneous%20microwave%20ablation%20assisted%20by%20three-dimensional%20visualization%20operative%20treatment%20planning%20system%20and%20percutaneous%20transhepatic%20cholangial%20drainage%20with%20intraductal%20chilled%20saline%20perfusion%20for%20larger%20hepatic%20hilum%20hepatocellular%20(D%20%E2%89%A5%203%20cm):%20preliminary%20results&rft.jtitle=Oncotarget&rft.au=Li,%20Xin&rft.date=2017-10-03&rft.volume=8&rft.issue=45&rft.spage=79742&rft.epage=79749&rft.pages=79742-79749&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.19275&rft_dat=%3Cproquest_pubme%3E1961638678%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c356t-5ab2cc8453959830dbbd6afe0addc83dee22a5c0a4a0de9c6e1ac3453fd98a23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1961638678&rft_id=info:pmid/29108354&rfr_iscdi=true